{
  "name": "DLBCL",
  "remarks": [
    "Module Describing Clinical Treatment of Diffuse Large B-Cell Lymphoma.",
    "Starts from initial, and covers DLBCL symptoms, diagnosis, staging, and treatment. Chance of survival is assigned based upon diagnosed cancer stage, and alligns with 5-year DLBCL survival rates, as reported by NCI SEER. Module aligns with mCODE data elements where possible. ",
    "",
    "Primary sources for information gathering:",
    "1) NCI SEER: https://seer.cancer.gov/statfacts/html/dlbcl.html",
    "2) Lymphoma Research Foundation: https://lymphoma.org/",
    "3) American Cancer Society: https://www.cancer.org/cancer/non-hodgkin-lymphoma/",
    "4) Official Journal of the National Comprehensive Cancer Network: https://jnccn.org/",
    "5) Conversation with Dr. William A. Wood, UNC hematologist and oncologist with a clinical focus in blood cancers",
    "6) Conversation with Dr. Miguel-Angel Perales, MSKCC Chief, Adult Bone Marrow Transplant Service",
    "",
    "",
    "",
    ""
  ],
  "states": {
    "Initial": {
      "type": "Initial",
      "conditional_transition": [
        {
          "transition": "Female",
          "condition": {
            "condition_type": "Gender",
            "gender": "F"
          }
        },
        {
          "transition": "Male",
          "condition": {
            "condition_type": "Gender",
            "gender": "M"
          }
        }
      ]
    },
    "Terminal": {
      "type": "Terminal"
    },
    "Male": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Terminal",
          "distribution": 0.9756
        },
        {
          "transition": "Pre- DLBCL",
          "distribution": 0.0244
        }
      ],
      "remarks": [
        "https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html#:~:text=Overall%2C%20the%20chance%20that%20a,%2C%20teens%2C%20and%20young%20adults",
        "the chance that a man will develop NHL in his lifetime is about 1 in 41"
      ]
    },
    "Female": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Terminal",
          "distribution": 0.9807999999999999
        },
        {
          "transition": "Pre- DLBCL",
          "distribution": 0.0192
        }
      ],
      "remarks": [
        "https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html#:~:text=Overall%2C%20the%20chance%20that%20a,%2C%20teens%2C%20and%20young%20adults",
        "for a woman, the risk is about 1 in 52"
      ]
    },
    "Pre- DLBCL": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Age 0-34",
          "distribution": 0.065
        },
        {
          "transition": "Age 75-140",
          "distribution": 0.289
        },
        {
          "transition": "Age 55-74",
          "distribution": 0.462
        },
        {
          "transition": "Age 35-54",
          "distribution": 0.185
        }
      ]
    },
    "Age 0-34": {
      "type": "Delay",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html",
        "Percent of New Cases by Age Group (all races and both sexes)",
        "<20 years old: 1.3%",
        "20-34 years old: 5.2%"
      ],
      "range": {
        "low": 0,
        "high": 34,
        "unit": "years"
      },
      "direct_transition": "DLBCL_Symptom1"
    },
    "Age 35-54": {
      "type": "Delay",
      "range": {
        "low": 35,
        "high": 54,
        "unit": "years"
      },
      "direct_transition": "DLBCL_Symptom1",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html",
        "Percent of New Cases by Age Group (all races and both sexes)",
        "35-44 years old: 6.2%",
        "45-54 years old: 12.3%"
      ]
    },
    "Age 55-74": {
      "type": "Delay",
      "range": {
        "low": 55,
        "high": 74,
        "unit": "years"
      },
      "direct_transition": "DLBCL_Symptom1",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html",
        "Percent of New Cases by Age Group (all races and both sexes)",
        "55-64 years old: 21.2%",
        "65-74 years old: 25.0%"
      ]
    },
    "Age 75-140": {
      "type": "Delay",
      "range": {
        "low": 75,
        "high": 140,
        "unit": "years"
      },
      "direct_transition": "DLBCL_Symptom1",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html",
        "Percent of New Cases by Age Group (all races and both sexes)",
        "75-84 years old: 20.1%",
        ">84 years old: 8.8%"
      ]
    },
    "DLBCL_Symptom1": {
      "type": "Symptom",
      "symptom": "Painless, Rapid Swelling of Lymph Nodes in Neck, Underarms, or Groin",
      "cause": "",
      "probability": 0.6,
      "direct_transition": "DLBCL_Symptom4",
      "exact": {
        "quantity": 1
      },
      "remarks": [
        "https://lymphoma.org/wp-content/uploads/2018/05/LRF_FACTSHEET_DIFFUSE_LRG_BCELL_LYMPHOMA_DLBCL.pdf"
      ]
    },
    "DLBCL_Symptom4": {
      "type": "Symptom",
      "symptom": "B Symptoms (fever, night sweats, and weight loss)",
      "cause": "",
      "probability": 0.3,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "DLBCL_Symptom5",
      "remarks": [
        "https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq"
      ]
    },
    "DLBCL_Symptom5": {
      "type": "Symptom",
      "symptom": "Fatigue",
      "cause": "",
      "probability": 1,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "DLBCL_Symptom6",
      "remarks": [
        "https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq"
      ]
    },
    "DLBCL_Symptom6": {
      "type": "Symptom",
      "symptom": "Loss of Appetite",
      "cause": "",
      "probability": 1,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "DLBCL_Symptom7",
      "remarks": [
        "https://lymphoma.org/wp-content/uploads/2018/05/LRF_FACTSHEET_DIFFUSE_LRG_BCELL_LYMPHOMA_DLBCL.pdf"
      ]
    },
    "DLBCL_Symptom7": {
      "type": "Symptom",
      "symptom": "Shortness of Breath",
      "cause": "",
      "probability": 1,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "Time Before Initial Doctor Visit",
      "remarks": [
        "https://lymphoma.org/wp-content/uploads/2018/05/LRF_FACTSHEET_DIFFUSE_LRG_BCELL_LYMPHOMA_DLBCL.pdf"
      ]
    },
    "Time Before Initial Doctor Visit": {
      "type": "Delay",
      "range": {
        "low": 0,
        "high": 1,
        "unit": "weeks"
      },
      "direct_transition": "Diffuse Large B-Cell Lymphoma Diagnosis Encounter I"
    },
    "Physical Exam": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 5880005,
          "display": "Physical Examination Procedure (procedure)"
        }
      ],
      "duration": {
        "low": 30,
        "high": 45,
        "unit": "minutes"
      },
      "direct_transition": "Blood Tests",
      "remarks": [
        "https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq"
      ]
    },
    "Blood Tests": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 396550006,
          "display": "Blood test (procedure)"
        }
      ],
      "duration": {
        "low": 10,
        "high": 15,
        "unit": "minutes"
      },
      "direct_transition": "Lymph Node Biopsy",
      "remarks": [
        "CBC, LDH, Hep B, uric acid, metabolic panel",
        "https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq"
      ]
    },
    "Lymph Node Biopsy": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 21911005,
          "display": "Biopsy of lymph node (Procedure)"
        }
      ],
      "duration": {
        "low": 10,
        "high": 45,
        "unit": "minutes"
      },
      "direct_transition": "End Diagnosis Encounter I",
      "remarks": [
        "https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq"
      ]
    },
    "DLBCL Found": {
      "type": "ConditionOnset",
      "assign_to_attribute": "DLBCL_Condition",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 109969005,
          "display": "Diffuse non-Hodgkins Lymphoma Large Cell (Disorder)"
        }
      ],
      "direct_transition": "Diagnosis Encounter II",
      "target_encounter": "Diagnosis Encounter II"
    },
    "PET-CT Scan": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 450436003,
          "display": "Positron emission tomography with computed tomography (procedure)"
        }
      ],
      "duration": {
        "low": 30,
        "high": 60,
        "unit": "minutes"
      },
      "reason": "DLBCL_Condition",
      "direct_transition": "Staging",
      "remarks": [
        "https://lymphoma.org/wp-content/uploads/2018/05/LRF_FACTSHEET_DIFFUSE_LRG_BCELL_LYMPHOMA_DLBCL.pdf"
      ]
    },
    "Staging": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Stage IV",
          "distribution": 0.34
        },
        {
          "transition": "Stage I",
          "distribution": 0.24
        },
        {
          "transition": "Stage II",
          "distribution": 0.19
        },
        {
          "transition": "Stage III",
          "distribution": 0.17
        },
        {
          "transition": "Unknown Stage",
          "distribution": 0.05
        }
      ]
    },
    "Stage I": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "21908-9",
          "display": "Stage group.clinical Cancer"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": 30440004,
        "display": "Lymphoma Stage I"
      },
      "direct_transition": "End Diagnosis Encounter II",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html"
      ]
    },
    "Stage II": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "21908-9",
          "display": "Stage group.clinical Cancer"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": 76422004,
        "display": "Lymphoma Stage II"
      },
      "direct_transition": "End Diagnosis Encounter II",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html"
      ]
    },
    "Stage III": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "21908-9",
          "display": "Stage group.clinical Cancer"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": 56944001,
        "display": "Lymphoma Stage III"
      },
      "direct_transition": "End Diagnosis Encounter II",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html"
      ]
    },
    "Stage IV": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "21908-9",
          "display": "Stage group.clinical Cancer"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": 66445009,
        "display": "Lymphoma Stage IV"
      },
      "direct_transition": "End Diagnosis Encounter II",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html"
      ]
    },
    "Unknown Stage": {
      "type": "Simple",
      "direct_transition": "End Diagnosis Encounter II",
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html"
      ]
    },
    "Diffuse Large B-cell Lymphoma Treatment Success Rate": {
      "type": "Simple",
      "conditional_transition": [
        {
          "transition": "Stage I Treatment",
          "condition": {
            "condition_type": "PriorState",
            "name": "Stage I"
          }
        },
        {
          "transition": "Stage II Treatment",
          "condition": {
            "condition_type": "PriorState",
            "name": "Stage II"
          }
        },
        {
          "transition": "Stage III Treatment",
          "condition": {
            "condition_type": "PriorState",
            "name": "Stage III"
          }
        },
        {
          "transition": "Stage IV Treatment",
          "condition": {
            "condition_type": "PriorState",
            "name": "Stage IV"
          }
        },
        {
          "transition": "Unknown Stage Treatment",
          "condition": {
            "condition_type": "PriorState",
            "name": "Unknown Stage"
          }
        }
      ]
    },
    "Stage I Treatment": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Treatment Successful",
          "distribution": 0.733
        },
        {
          "transition": "Treatment Unsuccessful",
          "distribution": 0.2669999999999999
        }
      ],
      "remarks": [
        "5-year relative survival rate by stage:",
        "Stage I – 73.3%",
        "https://seer.cancer.gov/statfacts/html/dlbcl.html"
      ]
    },
    "Stage II Treatment": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Treatment Successful",
          "distribution": 0.727
        },
        {
          "transition": "Treatment Unsuccessful",
          "distribution": 0.27300000000000013
        }
      ],
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html",
        "5-year relative survival rate by stage:",
        "Stage II – 72.7%"
      ]
    },
    "Stage III Treatment": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Treatment Unsuccessful",
          "distribution": 0.363
        },
        {
          "transition": "Treatment Successful",
          "distribution": 0.637
        }
      ],
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html",
        "5-year relative survival rate by stage:",
        "Stage III – 63.7%"
      ]
    },
    "Stage IV Treatment": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Treatment Successful",
          "distribution": 0.527
        },
        {
          "transition": "Treatment Unsuccessful",
          "distribution": 0.47299999999999986
        }
      ],
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html",
        "5-year relative survival rate by stage",
        "Stage IV – 52.7%"
      ]
    },
    "Unknown Stage Treatment": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "Treatment Unsuccessful",
          "distribution": 0.42300000000000004
        },
        {
          "transition": "Treatment Successful",
          "distribution": 0.577
        }
      ],
      "remarks": [
        "https://seer.cancer.gov/statfacts/html/dlbcl.html",
        "5-year relative survival rate by stage:",
        "Unknown – 57.7%"
      ]
    },
    "Treatment Unsuccessful": {
      "type": "SetAttribute",
      "attribute": "DLBCL_Survival",
      "value": "No",
      "direct_transition": "Impending Death from Cancer Complications"
    },
    "Treatment Successful": {
      "type": "SetAttribute",
      "attribute": "DLBCL_Survival",
      "value": "Yes",
      "direct_transition": "Meet with Oncologist for Treatment Options"
    },
    "Impending Death from Cancer Complications": {
      "type": "Death",
      "range": {
        "low": 2,
        "high": 5,
        "unit": "years"
      },
      "referenced_by_attribute": "DLBCL_Condition",
      "direct_transition": "Meet with Oncologist for Treatment Options"
    },
    "Meet with Oncologist for Treatment Options": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 223484005,
          "display": "Discussion about treatment (procedure)"
        }
      ],
      "reason": "DLBCL_Condition",
      "direct_transition": "End Meeting with Oncologist for Treatment Options"
    },
    "Choose Treatment Option": {
      "type": "Delay",
      "range": {
        "low": 1,
        "high": 7,
        "unit": "days"
      },
      "conditional_transition": [
        {
          "transition": "Stage I/II Treatment Round 1",
          "condition": {
            "condition_type": "Or",
            "conditions": [
              {
                "condition_type": "PriorState",
                "name": "Stage I Treatment"
              },
              {
                "condition_type": "PriorState",
                "name": "Stage II Treatment"
              }
            ]
          }
        },
        {
          "transition": "Stage III/IV Treatment Round 1",
          "condition": {
            "condition_type": "Or",
            "conditions": [
              {
                "condition_type": "PriorState",
                "name": "Stage III Treatment"
              },
              {
                "condition_type": "PriorState",
                "name": "Stage IV Treatment"
              }
            ]
          }
        },
        {
          "transition": "Stage I/II Treatment Round 1"
        }
      ]
    },
    "Meet_with_Oncologist_after_First_Round": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 223484005,
          "display": "Discussion about treatment (procedure)"
        }
      ],
      "direct_transition": "End Meeting with Oncologist after First Round Treatment",
      "reason": "DLBCL_Condition"
    },
    "End Meeting with Oncologist after First Round Treatment": {
      "type": "EncounterEnd",
      "direct_transition": "Delay Before Second-Line Treatment"
    },
    "End meeting with Oncologist": {
      "type": "EncounterEnd",
      "direct_transition": "Waiting for Car-T Procedure"
    },
    "Kymriah Infusion": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": 1986442,
          "display": "Tisagenlecleucel 250000000 Cells Injection"
        }
      ],
      "direct_transition": "End CAR-T therapy treatment encounter",
      "assign_to_attribute": "CAR-T_therapy",
      "reason": "DLBCL_Condition",
      "remarks": [
        "https://www.cancer.gov/about-cancer/treatment/research/car-t-cells"
      ]
    },
    "Yescarta Infusion": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": 1987402,
          "display": "Axicabtagene ciloleucel 200000000 Cells Injection"
        }
      ],
      "direct_transition": "End CAR-T therapy treatment encounter",
      "assign_to_attribute": "CAR-T_therapy",
      "reason": "DLBCL_Condition",
      "remarks": [
        "https://lymphoma.org/wp-content/uploads/2018/05/LRF_FACTSHEET_DIFFUSE_LRG_BCELL_LYMPHOMA_DLBCL.pdf"
      ]
    },
    "Patient is monitored in hospital for 1-3 weeks": {
      "type": "Delay",
      "range": {
        "low": 1,
        "high": 3,
        "unit": "weeks"
      },
      "direct_transition": "CAR-T therapy side effect 1"
    },
    "Meet_with_Oncologist": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "reason": "DLBCL_Condition",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 223484005,
          "display": "Discussion about treatment (procedure)"
        }
      ],
      "direct_transition": "End meeting with Oncologist"
    },
    "Risk/Recovery Period for 2-3 months ": {
      "type": "Delay",
      "direct_transition": "Follow-up after CAR-T therapy",
      "range": {
        "low": 2,
        "high": 3,
        "unit": "months"
      },
      "remarks": [
        "https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/faq-about-car-t-cell-therapy/"
      ]
    },
    "PET-CT_Scan": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 450436003,
          "display": "Positron emission tomography with computed tomography (procedure)"
        }
      ],
      "duration": {
        "low": 30,
        "high": 60,
        "unit": "minutes"
      },
      "direct_transition": "End Follow-up CAR-T therapy encounter",
      "reason": "DLBCL_Condition"
    },
    "First 30 days after discharge patient remains close to hospital": {
      "type": "Simple",
      "direct_transition": "Risk/Recovery Period for 2-3 months ",
      "remarks": [
        "https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/faq-about-car-t-cell-therapy/"
      ]
    },
    "Lymphodepleting Chemotherapy": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 367336001,
          "display": "Chemotherapy (procedure)"
        }
      ],
      "duration": {
        "low": 30,
        "high": 240,
        "unit": "minutes"
      },
      "direct_transition": "Cyclophosphamide"
    },
    "Cyclophosphamide": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": 1734919,
          "display": "Cyclophosphamide 100MG injection"
        }
      ],
      "direct_transition": "Fludarabine",
      "reason": "DLBCL_Condition",
      "remarks": [
        "Fludarabine and cyclophosphamide are two types of chemotherapy drugs used in lymphodepletion. ",
        "https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2019-05612#:~:text=Fludarabine%20and%20cyclophosphamide%20are%20two%20types%20of%20chemotherapy,the%20body%20before%20tumor%20infiltrating%20lymphocytes%20are%20infused."
      ]
    },
    "Fludarabine": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": 1740865,
          "display": "2 ML Fludarabine phosphate 25 MG/ML injection"
        }
      ],
      "distributed_transition": [
        {
          "transition": "Kymriah Infusion",
          "distribution": 0.25
        },
        {
          "transition": "Yescarta Infusion",
          "distribution": 0.75
        }
      ],
      "reason": "DLBCL_Condition",
      "remarks": [
        "Fludarabine and cyclophosphamide are two types of chemotherapy drugs used in lymphodepletion. ",
        "75-25 split between administered CAR-T drugs in practice today was informed by Dr. Perales.",
        "https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2019-05612#:~:text=Fludarabine%20and%20cyclophosphamide%20are%20two%20types%20of%20chemotherapy,the%20body%20before%20tumor%20infiltrating%20lymphocytes%20are%20infused."
      ]
    },
    "CAR-T Therapy Treatment Effective": {
      "type": "Observation",
      "category": "therapy",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "88040-1",
          "display": "Response to cancer treatment"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": 268910001,
        "display": "Patient condition improved (finding)"
      },
      "direct_transition": "Delay Before Meeting for Discharge"
    },
    "CAR-T Therapy Treatment Ineffective": {
      "type": "Observation",
      "category": "therapy",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "88040-1",
          "display": "Response to cancer treatment"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": 271299001,
        "display": "Patient condition worsened (finding)"
      },
      "direct_transition": "Terminal"
    },
    "Blood tests after CAR-T therapy": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 396550006,
          "display": "Blood test (procedure)"
        }
      ],
      "duration": {
        "low": 10,
        "high": 15,
        "unit": "minutes"
      },
      "direct_transition": "PET-CT_Scan",
      "reason": "DLBCL_Condition",
      "remarks": [
        "https://www.yescarta.com/"
      ]
    },
    "End Meeting with Oncologist for Treatment Options": {
      "type": "EncounterEnd",
      "direct_transition": "Choose Treatment Option"
    },
    "Stage I/II Treatment Round 1": {
      "type": "CallSubmodule",
      "submodule": "dlbcl/dlbcl_stage_i_ii_treatment_round_one",
      "conditional_transition": [
        {
          "transition": "Delay Before Meeting for Discharge",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "Treatment_1_Outcome",
            "operator": "==",
            "value": "Remission"
          }
        },
        {
          "transition": "Delay before post-1st round discussion",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "Treatment_1_Outcome",
            "operator": "==",
            "value": "Worsened"
          }
        }
      ]
    },
    "Stage III/IV Treatment Round 1": {
      "type": "CallSubmodule",
      "submodule": "dlbcl/dlbcl_stage_iii_iv_treatment_round_one",
      "conditional_transition": [
        {
          "transition": "Delay before post-1st round discussion",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "Treatment_1_Outcome",
            "operator": "==",
            "value": "Worsened"
          }
        },
        {
          "transition": "Delay Before Meeting for Discharge",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "Treatment_1_Outcome",
            "operator": "==",
            "value": "Remission"
          }
        }
      ]
    },
    "End Diagnosis Encounter I": {
      "type": "EncounterEnd",
      "direct_transition": "Time for Initial Diagnostic Testing"
    },
    "Diffuse Large B-Cell Lymphoma Diagnosis Encounter I": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 185345009,
          "display": "Encounter for Symptom (Procedure)"
        }
      ],
      "direct_transition": "Physical Exam"
    },
    "Diagnosis Encounter II": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "reason": "DLBCL_Condition",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 185347001,
          "display": "Encounter for problem (procedure)"
        }
      ],
      "direct_transition": "PET-CT Scan"
    },
    "Patient's cells are genetically modified": {
      "type": "Delay",
      "range": {
        "low": 2,
        "high": 4,
        "unit": "weeks"
      },
      "direct_transition": "CAR-T Therapy Treatment",
      "remarks": [
        "https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/how-car-t-cell-therapy-works/",
        "Delay time was confirmed by Dr. Wood and Dr. Perales",
        ""
      ]
    },
    "End CAR-T therapy treatment encounter": {
      "type": "EncounterEnd",
      "direct_transition": "Patient is monitored in hospital for 1-3 weeks"
    },
    "Follow-up after CAR-T therapy": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 185389009,
          "display": "Follow-up visit (procedure)"
        }
      ],
      "direct_transition": "Blood tests after CAR-T therapy",
      "reason": "DLBCL_Condition"
    },
    "End Follow-up CAR-T therapy encounter": {
      "type": "EncounterEnd",
      "conditional_transition": [
        {
          "transition": "CAR-T Therapy Treatment Effective",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "DLBCL_Survival",
            "operator": "==",
            "value": "Yes"
          }
        },
        {
          "transition": "CAR-T Therapy Treatment Ineffective",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "DLBCL_Survival",
            "operator": "==",
            "value": "No"
          }
        }
      ]
    },
    "CAR-T therapy side effect 1": {
      "type": "Symptom",
      "symptom": "Cytokine Release Syndrome (flu-like, high fever/chills, low blood pressure, difficulty breathing, and confusion)",
      "cause": "",
      "probability": 0.58,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "CAR-T therapy side effect 2",
      "remarks": [
        "https://www.novartis.com/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult",
        "- cytokine release syndrome (CRS) occurred in 58% of all treated patients, with 23% of patients experiencing grade 3/4 CRS (using Penn Grading Scale)"
      ]
    },
    "CAR-T therapy side effect 2": {
      "type": "Symptom",
      "symptom": "Neurologic symptoms (confusion, difficulty understanding language, and speaking)",
      "cause": "",
      "probability": 0.21,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "CAR-T therapy side effect 3",
      "remarks": [
        "https://www.novartis.com/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult",
        "- Twenty one percent of patients experienced any grade neurologic events"
      ]
    },
    "CAR-T therapy side effect 3": {
      "type": "Symptom",
      "symptom": "Diarrhea",
      "cause": "",
      "probability": 1,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "CAR-T therapy side effect 4",
      "remarks": [
        "https://www.yescarta.com/"
      ]
    },
    "CAR-T therapy side effect 4": {
      "type": "Symptom",
      "symptom": "Nausea",
      "cause": "",
      "probability": 1,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "CAR-T therapy side effect 5",
      "remarks": [
        "https://www.yescarta.com/"
      ]
    },
    "CAR-T therapy side effect 5": {
      "type": "Symptom",
      "symptom": "Fast or irregular heartbeat",
      "cause": "",
      "probability": 1,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "CAR-T therapy side effect 6",
      "remarks": [
        "https://www.yescarta.com/"
      ]
    },
    "CAR-T therapy side effect 6": {
      "type": "Symptom",
      "symptom": "Low White Blood Cell Count",
      "cause": "",
      "probability": 1,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "CAR-T therapy side effect 7",
      "remarks": [
        "https://www.yescarta.com/"
      ]
    },
    "CAR-T therapy side effect 7": {
      "type": "Symptom",
      "symptom": "Low Red Blood Cell Count",
      "cause": "",
      "probability": 1,
      "exact": {
        "quantity": 1
      },
      "direct_transition": "First 30 days after discharge patient remains close to hospital",
      "remarks": [
        "https://www.yescarta.com/"
      ]
    },
    "CAR-T Initial Treatment Encounter": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "reason": "DLBCL_Condition",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 185347001,
          "display": "Encounter for problem (procedure)"
        }
      ],
      "direct_transition": "Leukopheresis"
    },
    "End_CAR_T_Initial_Treatment_Encounter": {
      "type": "EncounterEnd",
      "direct_transition": "Patient's cells are genetically modified"
    },
    "CAR-T Therapy Treatment": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "reason": "DLBCL_Condition",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 185347001,
          "display": "Encounter for problem (procedure)"
        }
      ],
      "direct_transition": "Lymphodepleting Chemotherapy"
    },
    "Leukopheresis": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 77257005,
          "display": "Leukopheresis (procedure)"
        }
      ],
      "duration": {
        "low": 3,
        "high": 4,
        "unit": "hours"
      },
      "reason": "",
      "direct_transition": "End_CAR_T_Initial_Treatment_Encounter",
      "remarks": [
        "https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/how-car-t-cell-therapy-works/"
      ]
    },
    "DLBCL_Treatment_Round_Two": {
      "type": "CallSubmodule",
      "submodule": "dlbcl/dlbcl_treatment_round_two",
      "conditional_transition": [
        {
          "transition": "Delay after Second-Line Treatment",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "Treatment_2_Outcome",
            "operator": "==",
            "value": "Worsened"
          }
        },
        {
          "transition": "Delay Before Meeting for Discharge",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "Treatment_2_Outcome",
            "operator": "==",
            "value": "Remission"
          }
        }
      ]
    },
    "Time for Initial Diagnostic Testing": {
      "type": "Delay",
      "direct_transition": "DLBCL Found",
      "range": {
        "low": 0,
        "high": 1,
        "unit": "weeks"
      }
    },
    "Delay for Analysis of Possible Treatmentss": {
      "type": "Delay",
      "direct_transition": "Diffuse Large B-cell Lymphoma Treatment Success Rate",
      "range": {
        "low": 1,
        "high": 7,
        "unit": "days"
      }
    },
    "End Diagnosis Encounter II": {
      "type": "EncounterEnd",
      "direct_transition": "Delay for Analysis of Possible Treatmentss"
    },
    "Delay before post-1st round discussion": {
      "type": "Delay",
      "direct_transition": "Meet_with_Oncologist_after_First_Round",
      "range": {
        "low": 1,
        "high": 7,
        "unit": "days"
      }
    },
    "Delay Before Meeting for Discharge": {
      "type": "Delay",
      "direct_transition": "Meet with Oncologist for Discharge",
      "range": {
        "low": 1,
        "high": 2,
        "unit": "months"
      },
      "remarks": [
        "https://www.cancer.org/treatment/survivorship-during-and-after-treatment/when-cancer-doesnt-go-away.html#:~:text=To%20qualify%20as%20either%20type,cancer%20definitely%20has%20been%20cured."
      ]
    },
    "Delay Before Second-Line Treatment": {
      "type": "Delay",
      "direct_transition": "DLBCL_Treatment_Round_Two",
      "range": {
        "low": 1,
        "high": 2,
        "unit": "weeks"
      }
    },
    "Delay after Second-Line Treatment": {
      "type": "Delay",
      "direct_transition": "Meet_with_Oncologist",
      "range": {
        "low": 0,
        "high": 1,
        "unit": "weeks"
      }
    },
    "Waiting for Car-T Procedure": {
      "type": "Delay",
      "direct_transition": "CAR-T Initial Treatment Encounter",
      "range": {
        "low": 0,
        "high": 2,
        "unit": "weeks"
      }
    },
    "DLBCL Remission": {
      "type": "ConditionEnd",
      "direct_transition": "Discharge",
      "referenced_by_attribute": "DLBCL_Condition"
    },
    "Meet with Oncologist for Discharge": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": 310513006,
          "display": "Discharge by medical oncologist (procedure)"
        }
      ],
      "direct_transition": "DLBCL Remission"
    },
    "Discharge": {
      "type": "EncounterEnd",
      "direct_transition": "Terminal"
    }
  }
}